A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
about
Radioresistance of Brain TumorsGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsCurrent Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaIdentification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomicsPhase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model.Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.Telomere profiling: toward glioblastoma personalized medicine.Cancer radioimmunotherapy.A stochastic cascade model for Auger-electron emitting radionuclides.Recent developments on immunotherapy for brain cancer.New therapeutic approaches for malignant glioma: in search of the Rosetta stoneImproving external beam radiotherapy by combination with internal irradiationTargeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted EffectsSplice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.Passive immunotherapeutic strategies for the treatment of malignant gliomas.Current concepts and management of glioblastoma.Targeting the epidermal growth factor receptor in solid tumor malignancies.The new golden era for radioimmunotherapy: not just for lymphomas anymore.Epidermal growth factor receptor as a therapeutic target in glioblastoma.General overview of radioimmunotherapy of solid tumors.Radioimmunotherapy for high-grade glioma.Targeted therapy in gliomas.Uptake, internalization and nuclear translocation of radioimmunotherapeutic agents.EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.Erlotinib: early clinical development in brain cancer.Glioblastoma multiforme: State of the art and future therapeutics.Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience.Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Immune and viral therapies for malignant primary brain tumors.EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.Contemporary management of high-grade gliomas.Current and emerging EGFR therapies for glioblastoma.EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model.Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
P2860
Q26752579-C39290D3-BA81-4E41-833B-B01542DDCF0EQ28082603-C0DC43B3-CE8E-48E9-A467-105358465C05Q28087306-F427D734-3114-4189-AAD6-6754FF9720C4Q28544645-61DD5939-C087-4A55-A075-A9FC6C412178Q33408024-B0890C04-4C4E-4D18-A206-906E4A0C064BQ34152633-06FE05FC-7B40-4E6F-AAD6-5764AF7D144FQ34286194-75D80AAC-9A66-4434-BD51-FA0C8A0FBACCQ34445288-8E8C0EA4-3E73-45BF-B1A9-F1268854A5E8Q35070045-A1473919-3374-4640-BBFC-747CC6232A77Q35968706-B99BC536-2655-4281-AABA-CE8A33EB8445Q35992355-008A940A-CBDC-4220-8D62-30E96DE3DC91Q36224493-98F015E8-9A59-4293-BB58-C455ECC22887Q36235732-0B476427-22A1-44D0-9A09-54C172EFB4D0Q36297064-119BB53C-DE9E-413A-AA1B-32E539B41EAAQ37267538-59C5F763-D376-4827-AB7D-2220076EDB24Q37690917-6240A157-E2EC-41AB-9F41-6317FAC9821FQ37714783-D17A3EB4-B996-404F-8574-131943CFB4F6Q37904921-55C8FE4C-A8F6-47AD-BE2E-4030D898C990Q37990044-A011935B-DDA2-4278-BC1F-3480AB860435Q38072815-50B194CF-D6A1-4A07-BF97-9A7250B9DB5CQ38098098-E811C899-D242-4E28-90C4-8FC6D6598B46Q38103579-8392CD9B-CB11-4382-896E-0256B3C67F57Q38110937-52413B68-1E5D-475F-8065-09872D419F40Q38186656-0C96EE05-1EB0-44C3-BE72-25F07BDFF220Q38193173-3A6C49C7-1B2B-48F7-8326-EE681260B9D0Q38199643-5F951C2E-7A46-4B66-8E2D-491F7651DD8EQ38212394-6BACD190-3ED7-4E6F-8AAE-18B10C534EAAQ38225874-F56723EC-21FA-4569-B8E2-388376D1764CQ38510365-2BBD6E29-34B1-41FF-8FA5-A59D7EA229D6Q38694765-E8456B7A-8EFF-4106-8F2E-65F1169A0E7EQ39168899-B628E751-EB83-4209-AEDF-48ECBD607010Q40089704-54D2EFB8-D2AA-40AB-B361-A0819BC35C00Q47130146-5532C98D-9B90-41B2-9985-DF0F97C17274Q47781482-A1318C02-1B14-41A2-A002-3974530F7016Q47878958-BF57A303-525E-45A7-BE90-F6D1134472F6Q48014727-D547A94E-78E3-49BB-95CE-46360C745187Q48458408-64C06D4C-6516-4EE0-BF1F-136FFEE56D57Q50100856-4160F5DF-C383-47DB-93A3-AC507B7114A8Q57153312-CAEFC486-741E-405E-9B8E-22C933F89DAD
P2860
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A Phase II study of anti-epide ...... nt of glioblastoma multiforme.
@en
A Phase II study of anti-epide ...... nt of glioblastoma multiforme.
@nl
type
label
A Phase II study of anti-epide ...... nt of glioblastoma multiforme.
@en
A Phase II study of anti-epide ...... nt of glioblastoma multiforme.
@nl
prefLabel
A Phase II study of anti-epide ...... nt of glioblastoma multiforme.
@en
A Phase II study of anti-epide ...... nt of glioblastoma multiforme.
@nl
P2093
P356
P1476
A Phase II study of anti-epide ...... nt of glioblastoma multiforme.
@en
P2093
Ed J Gracely
Jacqueline G Emrich
Joseph M Jenrette
Luther W Brady
Perry Black
Steven C Cohen
Theodore E Yaeger
Tony S Quang
P304
P356
10.3171/2010.2.JNS091211
P407
P577
2010-08-01T00:00:00Z